GlassScriptPhysician profile
Elizabeth Bunch
NPI 1699201327
$2,992.80
in general payments reported to CMS, 2019-2025
27 companies · $880 in 2025
The $880 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $98.40 · 2021: $582 · 2022: $400 · 2023: $559 · 2024: $473 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $897.85 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $422.86 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $292.96 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $235.28 | 2020-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $182.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $160.12 | 2025 | Auvelity, Symbravo |
| Esperion Therapeutics, INC. | $113.32 | 2020-2021 | |
| Exact Sciences Corporation | $90.89 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.60 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $79.10 | 2021-2025 | Otezla, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.30 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $49.48 | 2024-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $45.02 | 2025 | |
| Pfizer INC. | $44.30 | 2025 | |
| Eisai INC. | $29.10 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.46 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genzyme Corporation | $25.69 | 2025 | |
| Inspire Medical Systems, INC. | $23.68 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $19.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.27 | 2022 | |
| Amarin Pharma, INC. | $15.58 | 2021 | |
| Ibsa Pharma INC. | $15.16 | 2025 | Flector, Licart, Tirosint |
| Dexcom, INC. | $14.88 | 2021 | |
| Corcept Therapeutics | $13.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.